<?xml version="1.0" encoding="UTF-8"?>
<p id="p0210">Balxavir marboxil, with a brand name of Xofloza, can target to viral polymerase acidic protein (PA), block its endonuclease function, leading to the inhibition of virus mRNA transcription and effectively prevent influenza A virus infection [
 <xref rid="bib125" ref-type="bibr">[125]</xref>, 
 <xref rid="bib126" ref-type="bibr">[126]</xref>, 
 <xref rid="bib127" ref-type="bibr">[127]</xref>]. The antiviral spectrum of Xofloza includes seasonal influenza strains and influenza strains resistant to oseltamivir, significantly reducing the viral load compared with oseltamivir [
 <xref rid="bib128" ref-type="bibr">128</xref>]. T-705 is a new type of RNA polymerase inhibitor which can inhibit a wide range of viruses by directly entering into the viral RNA chain or by binding directly to the viral RNA polymerase domain to block viral RNA chain replication and transcription [
 <xref rid="bib129" ref-type="bibr">129</xref>,
 <xref rid="bib130" ref-type="bibr">130</xref>]. It has been approved for listing in Japan [
 <xref rid="bib131" ref-type="bibr">131</xref>,
 <xref rid="bib132" ref-type="bibr">132</xref>].
</p>
